NOTV 📈 Inotiv - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US45783Q1004
NOTV: Scientific Instruments, Research Models, Bioproducts, Software, Laboratory Services
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana. Web URL: https://www.inotivco.com
Additional Sources for NOTV Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
NOTV Stock Overview
Market Cap in USD | 123m |
Sector | Healthcare |
Industry | Diagnostics & Research |
GiC Sub-Industry | Life Sciences Tools & Services |
IPO / Inception | 1997-11-25 |
NOTV Stock Ratings
Growth 5y | -26.0% |
Fundamental | -44.9% |
Dividend | - |
Rel. Strength Industry | 190 |
Analysts | 4.33/5 |
Fair Price Momentum | 4.23 USD |
Fair Price DCF | - |
NOTV Dividends
No Dividends PaidNOTV Growth Ratios
Growth Correlation 3m | 88.9% |
Growth Correlation 12m | -50.5% |
Growth Correlation 5y | -42.5% |
CAGR 5y | -2.37% |
CAGR/Mean DD 5y | -0.04 |
Sharpe Ratio 12m | 0.77 |
Alpha | -29.08 |
Beta | 2.06 |
Volatility | 230.78% |
Current Volume | 1251.1k |
Average Volume 20d | 1541.9k |
What is the price of NOTV stocks?
As of December 21, 2024, the stock is trading at USD 4.08 with a total of 1,251,091 shares traded.
Over the past week, the price has changed by -31.43%, over one month by +27.10%, over three months by +137.90% and over the past year by +14.93%.
As of December 21, 2024, the stock is trading at USD 4.08 with a total of 1,251,091 shares traded.
Over the past week, the price has changed by -31.43%, over one month by +27.10%, over three months by +137.90% and over the past year by +14.93%.
Is Inotiv a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Inotiv (NASDAQ:NOTV) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -44.87 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NOTV as of December 2024 is 4.23. This means that NOTV is currently overvalued and has a potential downside of 3.68%.
Probably not. Based on ValueRay Fundamental Analyses, Inotiv (NASDAQ:NOTV) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -44.87 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NOTV as of December 2024 is 4.23. This means that NOTV is currently overvalued and has a potential downside of 3.68%.
Is NOTV a buy, sell or hold?
Inotiv has received a consensus analysts rating of 4.33. Therefor, it is recommend to buy NOTV.
Inotiv has received a consensus analysts rating of 4.33. Therefor, it is recommend to buy NOTV.
- Strong Buy: 2
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecast for NOTV stock price target?
According to ValueRays Forecast Model, NOTV Inotiv will be worth about 4.6 in December 2025. The stock is currently trading at 4.08. This means that the stock has a potential upside of +12.01%.
According to ValueRays Forecast Model, NOTV Inotiv will be worth about 4.6 in December 2025. The stock is currently trading at 4.08. This means that the stock has a potential upside of +12.01%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 6.7 | 63.5% |
Analysts Target Price | 15.1 | 269.1% |
ValueRay Target Price | 4.6 | 12% |